Skill Checkup: A 43-Year-Old Man With a History of Smoking and Current Pressure in the Middle of the Chest and Dyspnea

Romesh Khardori, MD, PhD, FACP

Disclosures

January 12, 2022

Cholesterol‐lowering treatments are indicated for patients with FH regardless of genetic test results. Early initiation of intensive LDL‐C‐lowering treatment is critical to reduce ASCVD morbidity and mortality. FH can usually be sufficiently treated with lipid‐lowering therapies, including statins, ezetimibe, bile acid sequestrants, niacin, and PCSK9 inhibitors. However, in patients 30-75 years of age with an LDL‐C level ≥ 100 mg/dL (≥ 2.6 mmol/L) on maximally tolerated statin and ezetimibe therapy, the addition of a PCSK9 inhibitor may be considered. An LDL‐C threshold of 70 mg/dL (1.8 mmol/L) is recommended before the addition of nonstatins to statin therapy. Niacin may also be beneficial for additional LDL‐C lowering in some patients with FH who are unable to achieve LDL‐C goals despite multidrug treatment regimens.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.

processing....